Chemical formula: C₅H₉Cl₂N₃O₂ Molecular mass: 214.05 g/mol PubChem compound: 2578
Carmustine is a cell-cycle phase nonspecific antineoplastic agent of the nitrosourea type. As an alkylating agent, it can alkylate reactive sites on nucleoproteins, thus interfering with DNA and RNA synthesis and DNA repair. In addition, carmustine is known to carbamoylate lysine residues on proteins causing irreversible inactivation of enzymes including glutathione reductase.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01AD01 | Carmustine | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01A Alkylating agents → L01AD Nitrosoureas |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| GLIADEL Implant | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| CARMUSTINE OBVIUS Powder and solvent for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Carmustine is an active ingredient of these brands:
United States (US)Australia (AU)Austria (AT)Brazil (BR)Canada (CA)Estonia (EE)Ireland (IE)Israel (IL)Japan (JP)New Zealand (NZ)South Africa (ZA)Tunisia (TN)Turkey (TR)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
